ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!Agenus Inc. (AGEN) stock declined over -8.63%, trading at $2.86 on NASDAQ, down from the previous close of $3.13. The stock opened at $3.18, fluctuating between $2.83 and $3.23 in the recent session.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Employees | 389 |
Beta | 1.3 |
Sales or Revenue | $156.31M |
5Y Sales Change% | 0.315% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Agenus Inc. (NASDAQ: AGEN) stock price is $2.86 in the last trading session. During the trading session, AGEN stock reached the peak price of $3.23 while $2.83 was the lowest point it dropped to. The percentage change in AGEN stock occurred in the recent session was -8.63% while the dollar amount for the price change in AGEN stock was -$0.27.
The NASDAQ listed AGEN is part of Biotechnology industry that operates in the broader Healthcare sector. Agenus Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Stephanie Fagan
Chief Communications Officer
Dr. Garo H. Armen Ph.D.
Executive Chairman
Ms. Tracy Mazza Clemente
Chief People Officer
Dr. Jennifer S. Buell Ph.D.
Pres, Chief Executive Officer & Director
Mr. Zack Armen
Head of Investor Relations
Mr. Dhan Chand
Scientific Director & Head of Drug Discovery
Ms. Christine M. Klaskin
Treasurer
Ms. Julie DeSander
Chief Bus. Officer
Craig Winter
Chief Information Officer
Regina Grebla Ph.D.
Vice President of Investor Relations & Communications
Dr. Steven J. O'Day M.D., Ph.D.
Chief Medical Officer
John Castle
Head of Translational Medicine & Bioinformatics
Ms. Robin E. Abrams J.D.
Chief Legal Officer
AGEN's closing price is 14.4% higher than its 52-week low of $2.50 where as its distance from 52-week high of $19.69 is -85.47%.
Number of AGEN employees currently stands at 389.
Official Website of AGEN is: https://www.agenusbio.com
AGEN could be contacted at phone 781 674 4400 and can also be accessed through its website. AGEN operates from 3 Forbes Road, Lexington, MA 02421-7305, United States.
AGEN stock volume for the day was 543.49K shares. The average number of AGEN shares traded daily for last 3 months was 423.15K.
The market value of AGEN currently stands at $67.09M with its latest stock price at $2.86 and 23.46M of its shares outstanding.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com